Biological characteristics of tumor necrosis factor-alpha-primed human umbilical cord mesenchymal stem cells

doi:10.12307/2023.673

Abstract

Abstract: BACKGROUND: In some preclinical and clinical studies, human umbilical cord mesenchymal stem cells have shown promising therapeutic results but limited efficacy. Therefore, enhancing the function of human umbilical cord mesenchymal stem cells by priming provides a new idea for the development of stem cell culture technology.
OBJECTIVE: To explore the changes of biological properties and mechanism of human umbilical cord mesenchymal stem cells primed with inflammatory factor tumor necrosis factor-α.
METHODS: The human umbilical cord mesenchymal stem cells were cultured to the sixth generation and primed with inflammatory factor tumor necrosis factor-α. The changes of immunomodulatory ability, anti-inflammatory function, surface markers, doubling time, and adipogenesis and osteogenesis ability were evaluated in control group and tumor necrosis factor-α-primed group of human umbilical cord mesenchymal stem cells. In addition, the transcriptome analysis of the two groups was compared to illustrate the precise mechanism.
RESULTS AND CONCLUSION: (1) Compared with the control group, different mass concentrations of tumor necrosis factor-α-primed human umbilical cord mesenchymal stem cells inhibited T cell proliferation and promoted Treg cell proliferation significantly. The effect of 1 ng/mL tumor necrosis factor-α was the most significant. (2) Compared with the control group, different mass concentrations of tumor necrosis factor-α-primed human umbilical cord mesenchymal stem cells released lower levels of tumor necrosis factor-α and higher levels of interleukin-10 in inflammatory model in vitro, and their anti-inflammatory ability was significantly enhanced. (3) There was no significant difference in cell multiplication time and surface marker expression between the control group and tumor necrosis factor-α-primed group, and both groups had strong osteogenic and lipogenic differentiation abilities. (4) Transcriptome changes between control group and tumor necrosis factor-α-primed group were mainly reflected in the activation of nuclear factor-κB signaling pathway and tumor necrosis factor-α signaling pathway. (5) These results indicated that tumor necrosis factor-α-primed human umbilical cord mesenchymal stem cells significantly enhanced their immunomodulatory and anti-inflammatory functions.

Key words: umbilical cord mesenchymal stem cell, inflammatory factor, prime, immune regulation, anti-inflammatory function, quality attribute, transcriptome expression profile, differentially expressed gene

CLC Number:

Chen Zili, Cao Ning, Xu Meng, Jiang Yan, Ji Meichao, Zheng Yangyang, Yang Lili. Biological characteristics of tumor necrosis factor-alpha-primed human umbilical cord mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(24): 3780-3787.

Figures/Tables 8

References

[1] DING DC, SHYU WC, LIN SZ. Mesenchymal stem cells. Cell Transplant. 2011; 20(1):5-14.
[2] SAMSONRAJ RM, RAGHUNATH M, NURCOMBE V, et al. Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. Stem Cells Transl Med. 2017;6(12):2173-2185.
[3] NAGAMURA-INOUE T, HE H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195-202.
[4] RAZA SS, SETH P, KHAN MA. ‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients. Stem Cell Rev Rep. 2021;17(1):153-162.
[5] NORONHA NC, MIZUKAMI A, CALIÁRI-OLIVEIRA C, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10(1):131.
[6] LEVY O, KUAI R, SIREN EMJ, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.
[7] DE WITTE SF, FRANQUESA M, BAAN CC, et al. Toward Development of iMesenchymal Stem Cells for Immunomodulatory Therapy. Front Immunol. 2016;6:648.
[8] ANDRZEJEWSKA A, LUKOMSKA B, JANOWSKI M. Concise Review: Mesenchymal Stem Cells: From Roots to Boost. Stem Cells. 2019;37(7):855-864.
[9] GALIPEAU J, KRAMPERA M, BARRETT J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151-159.
[10] ČAMERNIK K, MIHELIČ A, MIHALIČ R, et al. Comprehensive analysis of skeletal muscle- and bone-derived mesenchymal stem/stromal cells in patients with osteoarthritis and femoral neck fracture. Stem Cell Res Ther. 2020;11(1):146.
[11] VINARDELL T, SHEEHY EJ, BUCKLEY CT, et al. A comparison of the functionality and in vivo phenotypic stability of cartilaginous tissues engineered from different stem cell sources. Tissue Eng Part A. 2012;18(11-12):1161-1170.
[12] LOTFY A, SALAMA M, ZAHRAN F, et al. Characterization of mesenchymal stem cells derived from rat bone marrow and adipose tissue: a comparative study. Int J Stem Cells. 2014;7(2):135-142.
[13] LA ROCCA G, LO IACONO M, CORSELLO T, et al. Human Wharton’s jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther. 2013;8(1):100-113.
[14] ZHA K, LI X, YANG Z, et al. Heterogeneity of mesenchymal stem cells in cartilage regeneration: from characterization to application. NPJ Regen Med. 2021;6(1):14.
[15] DU W, LI X, CHI Y, et al. VCAM-1+ placenta chorionic villi-derived mesenchymal stem cells display potent pro-angiogenic activity. Stem Cell Res Ther. 2016;7:49.
[16] MIZUKAMI A, SWIECH K. Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization. Stem Cells Int. 2018;2018:4083921.
[17] NAJAR M, RAICEVIC G, FAYYAD-KAZAN H, et al. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy. 2016;18(2):160-171.
[18] NAVA MM, RAIMONDI MT, PIETRABISSA R. Controlling self-renewal and differentiation of stem cells via mechanical cues. J Biomed Biotechnol. 2012;2012:797410.
[19] LEROUX L, DESCAMPS B, TOJAIS NF, et al. Hypoxia preconditioned mesenchymal stem cells improve vascular and skeletal muscle fiber regeneration after ischemia through a Wnt4-dependent pathway. Mol Ther. 2010;18(8):1545-1452.
[20] 侯婧瑛,于萌蕾,郭天柱,等.缺氧预处理激活HIF-1α/MALAT1/VEGFA通路促进骨髓间充质干细胞生存和血管再生[J].中国组织工程研究, 2021,25(7): 985-990.
[21] BALDARI S, DI ROCCO G, PICCOLI M, et al. Challenges and Strategies for Improving the Regenerative Effects of Mesenchymal Stromal Cell-Based Therapies. Int J Mol Sci. 2017;18(10):2087.
[22] LINARES GR, CHIU CT, SCHEUING L, et al. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington’s disease. Exp Neurol. 2016;281:81-92.
[23] MEAD B, CHAMLING X, ZACK DJ, et al. TNFα-Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells. Invest Ophthalmol Vis Sci. 2020;61(2):6.
[24] SZABÓ E, FAJKA-BOJA R, KRISTON-PÁL É, et al. Licensing by Inflammatory Cytokines Abolishes Heterogeneity of Immunosuppressive Function of Mesenchymal Stem Cell Population. Stem Cells Dev. 2015;24(18):2171-2180.
[25] JIANG W, XU J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712.
[26] SHU J, HE X, ZHANG L, et al. Human amnion mesenchymal cells inhibit lipopolysaccharide-induced TNF-α and IL-1β production in THP-1 cells. Biol Res. 2015;48:69.
[27] PAJARINEN J, LIN T, GIBON E, et al. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials. 2019;196:80-89.
[28] RYAN JM, BARRY FP, MURPHY JM, et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8.
[29] DORRONSORO A, FERRIN I, SALCEDO JM, et al. Human mesenchymal stromal cells modulate T-cell responses through TNF-α-mediated activation of NF-κB. Eur J Immunol. 2014;44(2):480-488.